Tin tức & Cập nhật

Do GLP1 receptor agonists increase thyroid cancer risk?

Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.

Keeping blood sugar under control reduces CRC risk in people with diabetes

For individuals with diabetes mellitus (DM), optimal glycaemic control may protect against the risk of developing colonic adenoma and colorectal cancer (CRC), as reported in a population-based cohort study.

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

Patients using multiple insulin injections demonstrate no significant difference in changes to A1c, insulin requirements, or weight after a year of treatment with a sodium glucose transporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP1) receptor agonist, as shown in a study.

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.

[MIMS Education] Tổng quan về đau bụng kinh - P1

[Infographic] Tiền đái tháo đường: Mối nguy cơ ngày càng phổ biến

Trong thông tin mới nhất được đăng tải trên trang của Bộ Y Tế, tỷ lệ tiền đái tháo đường ở Việt Nam hiện đã ở mức hơn 17%.

SGLT2 inhibitors suitable for patients with T2D and NAFLD

Clinicians may favour prescribing sodium-glucose cotransporter 2 (SGLT2) inhibitors to patients with both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), with the drugs having potential benefits in terms of NAFLD regression and reduced incidences of adverse liver-related outcomes, according to a study.